Urine levels of HMGB1 in Systemic Lupus Erythematosus patients with and without renal manifestations

Arthritis Research and Therapy

Volumn 14, Issue 4, 2012, Pages

  Abdulahad, Deena A ^a   Westra, Johanna ^a   Bijzet, Johannes ^a   Dolff, Sebastian ^a,c   van Dijk, Marcory C ^a   Limburg, Pieter C ^a   Kallenberg, Cees G M ^a   Bijl, Marc ^b  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b MARTINI HOSPITAL   (Netherlands)

^c UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C4; HIGH MOBILITY GROUP B1 PROTEIN; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 9; BIOLOGICAL MARKER; HMGB1 PROTEIN, HUMAN;

ADOLESCENT; ADULT; AGED; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ACTIVITY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KIDNEY BIOPSY; KIDNEY INJURY; LUPUS ERYTHEMATOSUS NEPHRITIS; MAJOR CLINICAL STUDY; MALE; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN SECRETION; PROTEIN URINE LEVEL; SCORING SYSTEM; SYSTEMIC LUPUS ERYTHEMATOSUS; WESTERN BLOTTING; LUPUS ERYTHEMATOSUS, SYSTEMIC; LUPUS NEPHRITIS; MIDDLE AGED; URINE; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; FEMALE; HMGB1 PROTEIN; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; LUPUS NEPHRITIS; MALE; MIDDLE AGED; YOUNG ADULT;

EID: 84864930475     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar4015     Document Type: Article

References (28)

1. Austin HA, Boumpas DT, Vaughan EM, Balow JE. Predicting renal outcomes in severe lupus nephritis: contributions of clinical and histologic data. Kidney Int 1994, 45:544-550. 10.1038/ki.1994.70, 8164443.
2. Bono L, Cameron JS, Hicks JA. The very long-term prognosis and complications of lupus nephritis and its treatment. QJM 1999, 92:211-218. 10.1093/qjmed/92.4.211, 10396609.
3. Berden JH. Lupus nephritis. Kidney Int 1997, 52:538-558. 10.1038/ki.1997.365, 9264014.
4. Manson JJ, Ma A, Rogers P, Mason LJ, Berden JH, van der Vlag J, D'Cruz DP, Isenberg DA, Rahman A. Relationship between anti-dsDNA, anti-nucleosome and anti-alpha-actinin antibodies and markers of renal disease in patients with lupus nephritis: a prospective longitudinal study. Arthritis Res Ther 2009, 11:R154. 10.1186/ar2831, 2787270, 19828047.
5. Sasaki T, Muryoi T, Hatakeyama A, Suzuki M, Sato H, Seino J, Saito T, Yoshinaga K. Circulating anti-DNA immune complexes in active lupus nephritis. Am J Med 1991, 91:355-362. 10.1016/0002-9343(91)90152-N, 1951379.
6. Qing X, Pitashny M, Thomas DB, Barrat FJ, Hogarth MP, Putterman C. Pathogenic anti-DNA antibodies modulate gene expression in mesangial cells: involvement of HMGB1 in anti-DNA antibody-induced renal injury. Immunol Lett 2008, 121:61-73. 10.1016/j.imlet.2008.08.007, 2677706, 18822317.
7. Bell CW, Jiang W, Reich CF, Pisetsky DS. The extracellular release of HMGB1 during apoptotic cell death. Am J Physiol Cell Physiol 2006, 291:C1318-C1325. 10.1152/ajpcell.00616.2005, 16855214.
8. Landsman D, Bustin M. A signature for the HMG-1 box DNA-binding proteins. Bioessays 1993, 15:539-546. 10.1002/bies.950150807, 8135767.
9. Wang H, Vishnubhakat JM, Bloom O, Zhang M, Ombrellino M, Sama A, Tracey KJ. Proinflammatory cytokines (tumor necrosis factor and interleukin 1) stimulate release of high mobility group protein-1 by pituicytes. Surgery 1999, 126:389-392. 10.1016/S0039-6060(99)70182-0, 10455911.
10. Gardella S, Andrei C, Ferrera D, Lotti LV, Torrisi MR, Bianchi ME, Rubartelli A. The nuclear protein HMGB1 is secreted by monocytes via a non-classical, vesicle-mediated secretory pathway. EMBO Rep 2002, 3:995-1001. 10.1093/embo-reports/kvf198, 1307617, 12231511.
11. Harris HE, Raucci A. Alarmin(g) news about danger: workshop on innate danger signals and HMGB1. EMBO Rep 2006, 7:774-778. 1525157, 16858429.
12. Kokkola R, Andersson A, Mullins G, Ostberg T, Treutiger CJ, Arnold B, Nawroth P, Andersson U, Harris RA, Harris HE. RAGE is the major receptor for the proinflammatory activity of HMGB1 in rodent macrophages. Scand J Immunol 2005, 61:1-9. 10.1111/j.0300-9475.2005.01534.x, 15644117.
13. Tian J, Avalos AM, Mao SY, Chen B, Senthil K, Wu H, Parroche P, Drabic S, Golenbock D, Sirois C, Hua J, An LL, Audoly L, La Rosa G, Bierhaus A, Naworth P, Marshak-Rothstein A, Crow MK, Fitzgerald KA, Latz E, Kiener PA, Coyle AJ. Toll-like receptor 9-dependent activation by DNA-containing immune complexes is mediated by HMGB1 and RAGE. Nat Immunol 2007, 8:487-496.
14. Yu M, Wang H, Ding A, Golenbock DT, Latz E, Czura CJ, Fenton MJ, Tracey KJ, Yang H. HMGB1 signals through toll-like receptor (TLR) 4 and TLR2. Shock 2006, 26:174-179. 10.1097/01.shk.0000225404.51320.82, 16878026.
15. Abdulahad DA, Westra J, Bijzet J, Limburg PC, Kallenberg CG, Bijl M. High mobility group box 1 (HMGB1) and anti-HMGB1 antibodies and their relation to disease characteristics in systemic lupus erythematosus. Arthritis Res Ther 2011, 13:R71. 10.1186/ar3332, 3218880, 21548924.
16. Hayashi A, Nagafuchi H, Ito I, Hirota K, Yoshida M, Ozaki S. Lupus antibodies to the HMGB1 chromosomal protein: epitope mapping and association with disease activity. Mod Rheumatol 2009, 19:283-292. 10.1007/s10165-009-0151-7, 19214652.
17. Li J, Xie H, Wen T, Liu H, Zhu W, Chen X. Expression of High Mobility Group Box Chromosomal Protein 1 and Its Modulating Effects on Downstream Cytokines in Systemic Lupus Erythematosus. J Rheumatol 2010, 37:766-775. 10.3899/jrheum.090663, 20110525.
18. Casciola-Rosen LA, Anhalt G, Rosen A. Autoantigens targeted in systemic lupus erythematosus are clustered in two populations of surface structures on apoptotic keratinocytes. J Exp Med 1994, 179:1317-1330. 10.1084/jem.179.4.1317, 2191465, 7511686.
19. Weening JJ, D'Agati VD, Schwartz MM, Seshan SV, Alpers CE, Appel GB, Balow JE, Bruijn JA, Cook T, Ferrario F, Fogo AB, Ginzler EM, Hebert L, Hill G, Hill P, Jennette JC, Kong NC, Lesavre P, Lockshin M, Looi LM, Makino H, Moura LA, Nagata M. The classification of glomerulonephritis in systemic lupus erythematosus revisited. J Am Soc Nephrol 2004, 15:241-250. 10.1097/01.ASN.0000108969.21691.5D, 14747370.
20. Bruchfeld A, Qureshi AR, Lindholm B, Barany P, Yang L, Stenvinkel P, Tracey KJ. High Mobility Group Box Protein-1 correlates with renal function in chronic kidney disease (CKD). Mol Med 2008, 14:109-115. 10.1007/s00894-007-0256-x, 2258159, 18317568.
21. Bruchfeld A, Wendt M, Bratt J, Qureshi AR, Chavan S, Tracey KJ, Palmblad K, Gunnarsson I. High-mobility group box-1 protein (HMGB1) is increased in antineutrophilic cytoplasmatic antibody (ANCA)-associated vasculitis with renal manifestations. Mol Med 2011, 17:29-35. 3022976, 20844833.
22. Kim J, Sohn E, Kim CS, Jo K, Kim JS. The role of high-mobility group box-1 protein in the development of diabetic nephropathy. Am J Nephrol 2011, 33:524-529. 10.1159/000327992, 21606643.
23. Ma CY, Jiao YL, Zhang J, Yang QR, Zhang ZF, Shen YJ, Chen ZJ, Zhao YR. Elevated plasma level of HMGB1 is associated with disease activity and combined alterations with IFN-alpha and TNF-alpha in systemic lupus erythematosus. Rheumatol Int 2012, 32:395-402. 10.1007/s00296-010-1636-6, 21120500.
24. Oyama Y, Hashiguchi T, Taniguchi N, Tancharoen S, Uchimura T, Biswas KK, Kawahara K, Nitanda T, Umekita Y, Lotz M, Maruyama I. High-mobility group box-1 protein promotes granulomatous nephritis in adenine-induced nephropathy. Lab Invest 2010, 90:853-866. 10.1038/labinvest.2010.64, 3096665, 20231821.
25. Sato F, Maruyama S, Hayashi H, Sakamoto I, Yamada S, Uchimura T, Morita Y, Ito Y, Yuzawa Y, Maruyama I, Matsuo S. High mobility group box chromosomal protein 1 in patients with renal diseases. Nephron Clin Pract 2008, 108:c194-c201. 10.1159/000118942, 18311084.
26. Zickert A, Palmblad K, Sundelin B, Chavan S, Tracey KJ, Bruchfeld A, Gunnarsson I. Renal expression and serum levels of high mobility group box 1 protein in lupus nephritis. Arthritis Res Ther 2012, 14:R36. 10.1186/ar3747, 3392835, 22348591.
27. Wada Y, Ito S, Ueno M, Nakano M, Arakawa M, Gejyo F. Renal outcome and predictors of clinical renal involvement in patients with silent lupus nephritis. Nephron Clin Pract 2004, 98:c105-111. 10.1159/000081551, 15627787.
28. Mao SY, Xu Y, Zhang J, Schifferli K, An LL, Leininger J, Kiener P, Wu H, Coyle AJ, Audoly LP. Antagonizing HMGB1 inhibits proteinuria in a murine model of lupus like disease. (abstract). J Immunol 2008, 178:131-124.